Successful Management of Primary Mediastinal Large B-cell Lymphoma during Pregnancy

• Published in: Internal Medicine Vol. 58; no. 23; pp. 3455 - 3459
• Main Authors: Hashimoto, Yoshinori, Omura, Hiromi, Tokuyasu, Yusuke, Nakamoto, Shu, Tanaka, Takayuki
• Format: Journal Article
• Language: English
• Published: Japan The Japanese Society of Internal Medicine 01.12.2019; Japan Science and Technology Agency
• Subjects: Adult; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B-cell lymphoma; Case Report; Chemotherapy; Complications; Cyclophosphamide - administration & dosage; Doxorubicin - administration & dosage; Female; Humans; Internal medicine; Lymphocytes B; Lymphoma; Lymphoma, Large B-Cell, Diffuse - drug therapy; Lymphoma, Large B-Cell, Diffuse - pathology; Male; Mediastinal Neoplasms - diagnosis; Mediastinal Neoplasms - drug therapy; Monoclonal antibodies; Prednisone - administration & dosage; Pregnancy; Pregnancy complications; Pregnancy Complications, Cardiovascular - drug therapy; Pregnancy Complications, Cardiovascular - etiology; Pregnancy Complications, Neoplastic - drug therapy; Pregnancy Trimester, Third; Prenatal Care - methods; primary mediastinal large B-cell lymphoma; Retrospective Studies; rituximab; Rituximab - administration & dosage; superior vena cava syndrome; Superior Vena Cava Syndrome - etiology; Targeted cancer therapy; Treatment Outcome; Vincristine - administration & dosage; primary mediastinal large B-cell lymphoma; superior vena cava syndrome; rituximab; pregnancy
• DOI: 10.2169/internalmedicine.3129-19
• ISSN: 0918-2918

We experienced a pregnant woman with superior vena cava syndrome at 15 weeks of pregnancy who was diagnosed with primary mediastinal large B-cell lymphoma and given chemotherapy. In this case, the clinical courses of both the mother and infant were favorable without any serious complications because of close multidisciplinary cooperation. Based on a retrospective review of this case, the administration of CHOP-like regimens during the second and third trimesters appears relatively safe. Because pregnancy and continuation of pregnancy are rare in patients with hematopoietic malignancies, the accumulation of detailed information is important.